- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01842880
MicroRNAs as Biomarkers in Patients With Chagas Disease
February 19, 2015 updated by: Milena Botelho Pereira Soares, Hospital Sao Rafael
Validation of MicroRNAs as Biomarkers for Determining Patients Prognosis With Chagas Disease
The purpose of this study is to analyze the efficacy of MicroRNAs as biomarkers on the Chagas Disease prognosis.
This analysis will be done through the correlation between the plasmatic levels of this molecule with functional and laboratory tests.
Study Overview
Status
Completed
Conditions
Detailed Description
The patients included in the study must at first sign the written consent. They shall be accompanied in the specialized outpatient clinics for Chagas disease - Hospital São Rafael - Centro de Biotecnologia e Terapia Celular. They will be submitted to several tests, including:
- Collection of Blood samples for biochemical analysis;
- Electrocardiogram;
- Holter Electrocardiogram;
- Echocardiogram;
- Treadmill Test;
- X-Ray Imaging;
- Magnetic Resonance Imaging;
- Evaluation of the quality of life through the application of questionnaires (SF 36 and the Minnesota Living With Heart Failure Questionnaire).
Study Type
Observational
Enrollment (Actual)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Bahia
-
Salvador, Bahia, Brazil, 41253-190
- Hospital Sao Rafael
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Tertiary Hospital
Description
Inclusion Criteria:
- Chagas disease diagnosis confirmed by 2 different serologies
- Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
Exclusion Criteria:
- Significant valve disease defined as aortic stenosis with a gradient of VE/Ao > 50 mmHg
- Mitral stenosis with a valve area inferior than 1,5 cm2
- Severe or moderate aortic and/or mitral regurgitation
- Chronic use of immunosuppressive agents
- Dialysis treatment of terminal renal failure
- Fever on the last 48 hours or evidence of systemic infection in activity according to the definition of sepsis of the ACCP/SCCM (American College os Chest Physicians/Society of Critical Care Medicine)
- Current abusive use of alcohol or illicit drugs (Based on the DSM IV)
- Any other comorbidities that impact patient's survival within the next 2 years
- Liver disease in activity
- Continuous use of steroids as treatment for COPD
- Hematologic, neoplastic or bone diseases
- Homeostasis disturbances
- Inflammatory diseases or chronic infectious diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Patients with Chagas disease diagnosis
Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation of plasmatic levels of MicroRNAs with the percentage of heart fibrosis
Time Frame: One year
|
Mensuration of heart fibrosis percentage with Magnetic Resonance Imaging
|
One year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation of plasmatic levels of MicroRNAs with the functional cardiovascular capacity
Time Frame: One year
|
Mensuration of the functional capacity with treadmill test.
|
One year
|
Correlation of plasmatic levels of MicroRNAs with the left ventricular function
Time Frame: One year
|
Mensuration of the left ventricular function with echocardiogram and magnetic resonance imaging
|
One year
|
Correlation of plasmatic levels of MicroRNAs with the serum levels of Pro-BNP.
Time Frame: One year
|
One year
|
|
Correlation of plasmatic levels of MicroRNAs with the serum levels of TNF-alpha
Time Frame: One year
|
One year
|
|
Correlation of plasmatic levels of MicroRNAs with the serum levels of IFN-gamma.
Time Frame: One year
|
One year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Milena Botelho Pereira Soares, PhD, Hospital Sao Rafael
- Study Chair: Carolina Thé Macedo, MD, Hospital Sao Rafael
- Study Director: Ricardo Ribeiro dos Santos, MD, Hospital Sao Rafael
- Study Chair: Ticiana Ferreira Larocca, MD, Hospital Sao Rafael
- Study Chair: Márcia Maria Noya Rabelo, MD, Hospital Sao Rafael
- Study Chair: Luís Cláudio Lemos Correia, MD, Hospital Sao Rafael
- Study Chair: Bruno Solano de Freitas Souza, MD, Hospital Sao Rafael
- Study Chair: Ana Luiza Dias Angelo, PhD, Hospital Sao Rafael
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2011
Primary Completion (Actual)
June 1, 2013
Study Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
April 23, 2013
First Submitted That Met QC Criteria
April 25, 2013
First Posted (Estimate)
April 30, 2013
Study Record Updates
Last Update Posted (Estimate)
February 20, 2015
Last Update Submitted That Met QC Criteria
February 19, 2015
Last Verified
February 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CEP-41-10-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chagas Disease
-
Drugs for Neglected DiseasesLAT ResearchCompletedChagas' DiseaseArgentina
-
Evandro Chagas Institute of Clinical ResearchNot yet recruitingChronic Chagas DiseaseBrazil
-
BayerCompleted
-
Drugs for Neglected DiseasesCompletedChagas' Disease (Chronic) NosSpain
-
Drugs for Neglected DiseasesEisai Co., Ltd.UnknownChronic Chagas Disease, IndeterminateBolivia
-
Juan D. MayaRecruitingChronic Chagas DiseaseChile
-
Institut de Recherche pour le DeveloppementInstituto de Investigación Hospital Universitario La PazCompletedChagas' Disease (Chronic) With Other Organ InvolvementBolivia
-
Drugs for Neglected DiseasesUnknownChagas Disease | Trypanosomiasis, South American | South American Trypanosomiasis | Disease, ChagasBolivia
-
Evandro Chagas National Institute of Infectious...National Institute of Cardiology, Laranjeiras, BrazilCompletedChagas Cardiomyopathy | Chagas DiseaseBrazil